Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. The company’s lead product, TMX-101, proved to have a good safety profile in humans during the first stage of a Phase I/II clinical trial for the localised treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

Tioga Pharmaceuticals is a virtual company developing the Phase III product candidate asimadoline for the treatment of diarrhea-predominant irritable bowel syndrome.